Toxicity with small molecule and immunotherapy combinations in non-small cell lung cancer

Treatment stratification in stage IV NSCLC is guided by identification of oncogene driver mutations. Actionable mutations with current licenced therapeutic agents include epidermal growth factor receptor (EGFR), rearrangements of anaplastic lymphoma kinase (ALK), ROS-1 and BRAF V600. Alongside progr...

Descripción completa

Detalles Bibliográficos
Autores principales: Adderley, H., Blackhall, F. H., Lindsay, C. R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7907017/
https://www.ncbi.nlm.nih.gov/pubmed/32915318
http://dx.doi.org/10.1007/s00262-020-02714-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7907017/
https://www.ncbi.nlm.nih.gov/pubmed/32915318
http://dx.doi.org/10.1007/s00262-020-02714-5

Ejemplares similares